Lmcg Investments LLC Lowers Stake in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• LMCG Investments LLC reduced its stake in Jazz Pharmaceuticals by 25.2% during the second quarter, now holding approximately 0.09% of the company valued at $5.9 million.
• Jazz Pharmaceuticals received positive analyst ratings, with a consensus "Moderate Buy" and a target price of $178.93, while several firms raised their price targets recently.
• Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals for around $490,000, marking a 0.85% decrease in his ownership.

Lmcg Investments LLC cut its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 25.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 55,641 shares of the specialty pharmaceutical company's stock after selling 18,729 shares during the quarter. Lmcg Investments LLC owned approximately 0.09% of Jazz Pharmaceuticals worth $5,905,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of JAZZ. Nuveen LLC acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter worth approximately $62,362,000. Fuller & Thaler Asset Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 41.7% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock worth $165,245,000 after acquiring an additional 391,660 shares during the last quarter. Perpetual Ltd boosted its position in shares of Jazz Pharmaceuticals by 60.2% in the first quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock worth $118,212,000 after acquiring an additional 357,784 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Jazz Pharmaceuticals by 14.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after acquiring an additional 293,360 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Jazz Pharmaceuticals by 147.7% in the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company's stock worth $43,652,000 after acquiring an additional 209,667 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on JAZZ. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 target price on the stock. The Goldman Sachs Group raised their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a research report on Friday, August 29th. Truist Financial lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Royal Bank Of Canada lifted their price target on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a research report on Thursday, August 28th. Finally, Morgan Stanley lifted their price target on shares of Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an "overweight" rating in a research report on Wednesday, September 24th. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $178.93.

Insider Activity

In other news, Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $140.00, for a total transaction of $490,000.00. Following the sale, the director owned 408,826 shares in the company, valued at $57,235,640. This trade represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 11,500 shares of company stock worth $1,525,280 in the last 90 days. Company insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Trading Down 2.0%

JAZZ opened at $135.43 on Friday. The firm has a market capitalization of $8.22 billion, a P/E ratio of -20.12, a P/E/G ratio of 8.48 and a beta of 0.28. The firm's 50 day moving average is $125.87 and its 200-day moving average is $115.76. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.